|
| Title |
Pub. Date |
Int. Class |
App. Num |
Applicant |
| 26. |
(WO 2008/013988) METHOD OF TREATING A CONDITION ASSOCIATED WITH PHOSPHORYLATION OF TASK-1
|
31.01.2008
|
A01N 37/18
|
PCT/US2007/016999
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
|
| |
This invention provides methods and compositions for treating a condition associated with phosphorylation of TASK-I in a subject comprising administering to the subject an amount of an agent effective to overcome the phosphorylation dependent loss of TASK-I function so as to thereby treat the condition. In a specific embodiment of the invention the agent is a TREK-I agonist.
|
| |
|
| 27. |
(WO 2008/013986) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC LIGHT TOXICITY
|
31.01.2008
|
C07K 14/00
|
PCT/US2007/016992
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
Methods are disclosed for treating ophthalmic conditions related to the production of toxic visual cycle products that accumulate in the eye, and are associated with reactions of the visual cycle during medical procedures that expose the eye to light, most commonly the various forms of ophthalmic surgery. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said treatments.
|
| |
|
| 28. |
(WO 2008/013985) USE OF HEAT SHOCK ACTIVATORS FOR TISSUE REGENERATION
|
31.01.2008
|
A61K 31/70
|
PCT/US2007/016991
|
UNIVERSITY OF FLORIDA
|
| |
The present invention generally provides therapeutic compositions and methods for treating a disease, disorder, or injury characterized by a deficiency in cell number. The method involves inducing a heat shock response in tissue or organ effected by disease and recruiting stem cells to repair or regenerate the disease-effected tissue.
|
| |
|
| 29. |
(WO 2008/013984) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC DISEASE
|
31.01.2008
|
C07K 14/00
|
PCT/US2007/016990
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
Methods are disclosed for treating or preventing ophthalmic conditions related to a toxic visual cycle product. Compounds and compositions useful in these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said the therapeutic and prophylactic methods of the invention.
|
| |
|
| 30. |
(WO 2008/013983) OPSIN STABILIZING COMPOUNDS AND METHODS OF USE
|
31.01.2008
|
C07K 14/00
|
PCT/US2007/016989
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
The present invention provides compositions and methods useful in the treatment and/or prevention of ophthalmic conditions and diseases, such as retinitis pigmentosa, that are dependent upon or related to misfolded opsin proteins in vivo. In addition, screening assays for agents useful in such treatment methods are described.
|
| |
|
| 31. |
(WO 2008/013975) METHODS AND KITS FOR MEASUREMENT OF LYMPHOCYTE FUNCTION
|
31.01.2008
|
G01N 33/00
|
PCT/US2007/016971
|
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
|
| |
The present invention provides simple and rapid methods for measuring the function of a desired subset of lymphocytes, for example, T cells, B cells or NK cells. In addition, the present invention provides an all-in-one kit that contains reagents which permit a rapid and reliable analysis of the functions of T cells, B cells and NK cells obtained directly from whole blood or cord blood.
|
| |
|
| 32. |
(WO 2008/013966) USE OF 8-QUINOLINOL AND ITS ANALOGS TO TARGET CANCER STEM CELLS
|
31.01.2008
|
A61K 31/47
|
PCT/US2007/016959
|
JOHNS HOPKINS UNIVERSITY
|
| |
8-quinolinol (8Q) and derivatives thereof for use in the treatment of proliferative diseases such as cancer, in particular slow metabolizing quiescent cancer stem cells.
|
| |
|
| 33. |
(WO 2008/013963) FATTY ACID AMIDE HYDROLASE INHIBITORS
|
31.01.2008
|
C07D 213/02
|
PCT/US2007/016953
|
UNIVERSITY OF CONNECTICUT
|
| |
Disclosed are compounds of formula R-X-Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CBl and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide...
|
| |
|
| 34. |
(WO 2008/013952) NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS FOR FABRICATING ARTIFICIAL RED BLOOD CELLS
|
31.01.2008
|
B82B 1/00
|
PCT/US2007/016935
|
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
|
| |
A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 μm to about 10 μm. The particles can also have a modulus configured such that a particle of the plurality of particles can pass through a tube having an inner diameter of less than about 3 μm.
|
| |
|
| 35. |
(WO 2008/013949) MOLECULAR DESIGN OF THERMOSTABLE ALCOHOL DEHYDROGENASE FOR SYNTHESIS FOR CHIRAL AROMATIC ALCOHOLS
|
31.01.2008
|
C07H 21/04
|
PCT/US2007/016929
|
MICHIGAN STATE UNIVERSITY
|
| |
The present invention relates to compositions and methods utilizing thermostable and novel alcohol dehydrogenase enzymes for biosynthesizing chiral specific molecules for use as precursor molecules in synthesizing pharmaceutical compounds. Particularly, in preferred embodiments, the invention relates to directed engineering of an enzymatic catalytic site of an alcohol dehydrogenase enzyme gene for enhancing enantioselectivity for (S)-enantiomer substrate catalytic activity for providing aryl (S)-enantiomer products in stereomeric excess.
|
| |
|
| 36. |
(WO 2008/013928) TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR
|
31.01.2008
|
A01N 43/04
|
PCT/US2007/016880
|
BIOGEN IDEC MA INC.
|
| |
The invention provides methods for cancer treatment, comprising administering to a subject in need of the treatment a combination therapy which comprises (a) administration of a TGF-β inhibitor and (b) a vector comprising an isolated polynucleotide which encodes an interferon polypeptide.
|
| |
|
| 37. |
(WO 2008/013927) ORGANIC LIGHT-EMITTING DIODES WITH NANOSTRUCTURE FILM ELECTRODE(S)
|
31.01.2008
|
H01L 29/861
|
PCT/US2007/016878
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
Organic light-emitting diodes (OLEDs) comprising at least one nanostructure-film electrode, and fabrication methods thereof are discussed. The nanostructure-film is preferably transparent, and may be deposited on a preferably-transparent substrate using a variety of techniques. A different material may be used to planarize the nanostructure-film and/or otherwise improve OLED performance.
|
| |
|
| 38. |
(WO 2008/013919) SIDEWALL TRACING NANOPROBES, METHOD FOR MAKING THE SAME, AND METHOD FOR USE
|
31.01.2008
|
B81B 1/00
|
PCT/US2007/016859
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
Sidewall tracing nanoprobes, in which the tip shape of the nanoprobe Is altered so that the diameter or width of the very tip of the probe is wider than the diameter of the supporting stem. Such side protruding probe tips are fabricated by a subtractive method of reducing the stem diameter, an additive method of increasing the tip diameter, or sideway bending of the probe tip. These sidewall tracing nanoprobes are useful for inspection of semiconductor devices, especially to quantitatively evaluate the defects on the side wall of trenches or via holes.
|
| |
|
| 39. |
(WO 2008/013910) METHODS FOR IDENTIFYING, DIAGNOSING, AND PREDICTING SURVIVAL OF LYMPHOMAS
|
31.01.2008
|
C12Q 1/68
|
PCT/US2007/016843
|
GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
|
| |
Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This in...
|
| |
|
| 40. |
(WO 2008/013900) OSTEOGENIC ENHANCER COMPOSITION
|
31.01.2008
|
A61K 38/00
|
PCT/US2007/016825
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
An osteogenic enhancer composition for bone and cartilage repair and methods of using the same are described.
|
| |
|
| 41. |
(WO 2008/013893) DIAGNOSIS AND TREATMENT OF AGE RELATED MACULAR DEGENERATION
|
31.01.2008
|
C12Q 1/68
|
PCT/US2007/016809
|
YALE UNIVERSITY
|
| |
Methods, compositions and kits for diagnosis and treatment of age related macular degeneration.
|
| |
|
| 42. |
(WO 2008/013880) GLASSES HAVING A REDUCED STRESS-OPTIC COEFFICIENT
|
31.01.2008
|
C03C 3/062
|
PCT/US2007/016784
|
DALHOUSIE UNIVERSITY
|
| |
The present invention provides novel glasses, methods of formulating glasses having a reduced stress-optic coefficient at visible wavelengths under anisotropic stress, and novel optical systems comprising a such glass.
|
| |
|
| 43. |
(WO 2008/013840) ERASTIN ANALOGS AND USES THEREOF
|
31.01.2008
|
A61K 31/497
|
PCT/US2007/016702
|
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
|
| |
The present invention relates to erastin analogs, particularly compounds of formulae VI, VIa, VII, and VIIa, as well as compounds 19, 20, and 20. The invention also relates to pharmaceutical compositions containing such analogs and to methods of treating condition in a mammal with such analogs and compositions.
|
| |
|
| 44. |
(WO 2008/013822) PARENTERAL PREPARATIONS OF GI-SAFER PHOSPHOLIPID-ASSOCIATED ANTI-INFLAMMATORIES AND METHODS OF PREPARATION AND USE
|
31.01.2008
|
A61K 9/127
|
PCT/US2007/016666
|
THE BOARD OF REGENT OF THE UNIVERSITY OF TEXAS SYSTEM
|
| |
Parenteral preparations of phospholipid-associated anti -inflammatories (PL- AIs) are described to treat pain/inflammation, with reduced gastrointestinal (GI) toxicity. The PL-AIs can be composed of phosphatidylcholine ('PC') associated with non-steroidal anti-inflammatory drugs ('NSAIDs'). To prepare the PL-AIs, a phospholipid is mixed with an NSAID in a polar solvent, solvent is removed, suspended in an aqueous medium and sterilized by filtration or other acceptable method. Alternatively, the phospholipid can be mixed with an injectable preparation of an NSAID. The PL-AIs, and particularly PC associated with the NSAIDs, indomethacin, ibuprofen or diclofenac are useful for treating Patent Ductus Arteriosus in low birth weight infants to re...
|
| |
|
| 45. |
(WO 2008/013820) BURIED CIRCUMFERENTIAL ELECTRODE MICROCAVITY PLASMA DEVICE ARRAYS, ELECTRICAL INTERCONNECTS, AND FORMATION METHOD
|
31.01.2008
|
H01J 17/04
|
PCT/US2007/016664
|
THE BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS
|
| |
A preferred embodiment microcavity plasma device array includes a plurality of first metal circumferential metal electrodes that surround microcavities in the device. The first circumferential electrodes are buried in a metal oxide layer and surround the microcavities in a plane transverse to the microcavity axis. A second electrode is arranged so as to be isolated from said first electrodes by said first metal oxide layer. In some embodiments, the second electrode is in a second layer, and in other embodiments the second electrode is also within the first metal oxide layer. A containing layer seals the discharge medium (plasma) into the microcavities. The electrodes form in a closed circumference around each microcavity in a plane transver...
|
| |
|
| 46. |
(WO 2008/013797) COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION
|
31.01.2008
|
A61K 39/395
|
PCT/US2007/016619
|
THE CLEVELAND CLINIC FOUNDATION
|
| |
The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the.agent inhibits ocular angiogenesis in the individual. In another embo...
|
| |
|
| 47. |
(WO 2008/013791) PAN-ANTAGONISTS FOR THE ANDROGEN RECEPTOR AND ANDROGEN RECEPTOR MUTANTS ASSOCIATED WITH ANTI-ANDROGEN WITHDRAWAL
|
31.01.2008
|
C07C 317/46
|
PCT/US2007/016611
|
UNIVERSITY OF DELAWARE
|
| |
Disclosed herein are compounds of formula (I) and formula (II), where R<sp>1</sp>-R<sp>4</sp> are as defined in the claims, which are antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of.currently prescribed anti-androgens and use of said antagonists in the treatment of androgen-dependent disorders, such as prostate cancer, acne, seborrhea, hirsutism, alopecia and hidradenitis suppurativa.
|
| |
|
| 48. |
(WO 2008/013737) COMPOSITIONS FOR REPROGRAMMING A CELL AND USES THEREFOR
|
31.01.2008
|
A61K 39/00
|
PCT/US2007/016402
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
The present invention generally provides therapeutic compositions and methods for treating a disease, disorder, or injury characterized by a deficiency in the number or biological activity of a cell of interest. The method provides compositions for generating reprogrammed cells or for increasing regeneration in a cell, tissue, or organ of interest. Such methods are useful for treating subjects having a deficiency in a particular cell type or in a polypeptide produced by that cell type. In particular, the invention provides prophylactic and therapeutic methods and compositions for ameliorating or preventing hyperglycemia associated with type 1 and type II diabetes and related complications.
|
| |
|
| 49. |
(WO 2008/013713) COAXIAL ELECTROSPUN FIBERS AND STRUCTURES AND METHODS OF FORMING SAME
|
31.01.2008
|
C12Q 1/68
|
PCT/US2007/016263
|
DUKE UNIVERSITY
|
| |
Nanofibers and microfibers having a core and a polymer shell surrounding the core are provided. The shell includes a plurality of channels that extend from an outer shell surface to the core, and one or more agents, such as pharmacological materials, proteins, viruses, plasmid DNA, bacterial cells, drug-loaded nanoparticles, are encapsulated within the core. The one or more agents discharge from the core through the channels at a controlled rate. The channels are formed by porogen material within the polymer shell.
|
| |
|
| 50. |
(WO 2008/013709) SYSTEM AND METHOD FOR INTRACRANIAL IMPLANTATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS
|
31.01.2008
|
A61M 5/178
|
PCT/US2007/016256
|
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
|
| |
A system and related method for delivering the anti-tumoral agent carmustine or other types of diagnostic or therapeutic agents into the brain of a patient with a brain tumor includes an insertion device, a skull mount, and a reformulated geometry of the carmustine compound (or other material) optimized for use in the insertion device and for maximized biodegradation time. The insertion device may be front loaded with the carmustine material (or other material) and inserted through the mount on a skull, to the location of the brain tumor, where the carmustine (or other material) is then released. It should be appreciated that the diagnostic and/or therapeutic system and related method thereof are not necessarily limited to the brain of a su...
|
| |
|
![[Back to Top]](/ipdl/include/backtop.gif){kind=small}
